<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6893760\results\search\country\results.xml">
  <result pre="biological properties [4,17,18,19]. In 2004, genotype PeV-A3 was discovered in" exact="Japan" post="followed by the discovery of PeV-A4 in the Netherlands"/>
  <result pre="in Japan followed by the discovery of PeV-A4 in the" exact="Netherlands" post="in 2006 [20]. Since then the number of PeV-A"/>
  <result pre="as part of the national EV surveillance programs in Japan," exact="Hong Kong," post="Denmark, Finland, the Netherlands, and the USA [14,15,38,39,40,41,42,43]. Furthermore,"/>
  <result pre="prevalence (23–57%) was recently demonstrated for PeV-A in children from" exact="Malawi" post="[33,44]. Specific PeV-A genotypic prevalence varies globally. In Europe"/>
  <result pre="but a higher diversity of genotypes has been reported in" exact="India" post="and Pakistan [47,48,49]. In the African continent, PeV-A1, A2,"/>
  <result pre="higher diversity of genotypes has been reported in India and" exact="Pakistan" post="[47,48,49]. In the African continent, PeV-A1, A2, and A3"/>
  <result pre="Different genotype distributions have further been reported, for example in" exact="Pakistan" post="and Ghana, underlining differences in prevalence and diversity between"/>
  <result pre="isolates [35,36]. However, a recent outbreak of neonatal sepsis in" exact="Australia" post="was caused by a recombinant PeV-A3 strain [52]. PeV-A"/>
  <result pre="other genotypes, has been reported to circulate biannually in the" exact="Netherlands" post="and Scotland [41,56]. Ultimately, epidemiological studies reporting PeV-A prevalence"/>
  <result pre="in adults based on reports from Finland, the Netherlands, and" exact="Japan" post="[57,58,59,60,61]. This is in line with clinical studies showing"/>
  <result pre="A6 nAbs is relatively high in Finland, the Netherlands, and" exact="Japan" post="[59,61]. Recently, a high overall seroprevalence (68.9%) of PeV-A3"/>
  <result pre="to PeV-A3 infection have also been recorded, most recently in" exact="Australia" post="[96,97,98,99,100]. Central nervous system (CNS) syndromes such as acute"/>
  <result pre="infections reported to the national enterovirus surveillance system in the" exact="United States," post="1983–2003Pediatr. Infect. Dis. J.20062588989310.1097/01.inf.0000237798.07462.3217006282 40.KhetsurianiN.Lamonte-FowlkesA.OberstS.PallanschM.A.collab: Centers for Disease Control"/>
  <result pre="der SandenS.de BruinE.VennemaH.SwaninkC.KoopmansM.van der AvoortH.Prevalence of human parechovirus in the" exact="Netherlands" post="in 2000 to 2007J. Clin. Microbiol.2008462884288910.1128/JCM.00168-0818614653 42.JanesV.A.MinnaarR.KoenG.van EijkH.Dijkman-de HaanK.PajkrtD.WolthersK.C.BenschopK.S.Presence"/>
  <result pre="type 1 diabetesJ. Med. Virol.20077945746210.1002/jmv.2083117311340 59.WesterhuisB.KolehmainenP.BenschopK.NurminenN.KoenG.KoskiniemiM.SimellO.KnipM.HyotyH.WolthersK.et al.Human parechovirus seroprevalence in" exact="Finland" post="and the NetherlandsJ. Clin. Virol.20135821121510.1016/j.jcv.2013.06.03623891146 60.TanakaS.AokiY.MatobaY.YahagiK.ItagakiT.MatsuzakiY.MizutaK.Seroepidemiology of human parechovirus"/>
  <result pre="Dis.2016221631163410.3201/eid2209.15149727532333 100.YamamotoM.AbeK.KuniyoriK.KuniiE.ItoF.KasamaY.YoshiokaY.NodaM.Epidemic of human parechovirus type 3 in Hiroshima city," exact="Japan" post="in 2008Jpn. J. Infect. Dis.20096224424519468194 101.Verboon-MaciolekM.A.GroenendaalF.HahnC.D.HellmannJ.van LoonA.M.BoivinG.de VriesL.S.Human parechovirus"/>
  <result pre="children up to 5 years with influenza-like illness in Northern" exact="Italy" post="during seven consecutive winter seasons (2010–2017)J. Gen. Virol.2017982699271110.1099/jgv.0.00093729106347 117.MladenovaZ.DikovaA.ThongprachumA.PetrovP.PekovaL.KomitovaR.Iturriza-GomaraM.UshijimaH.Diversity"/>
 </snippets>
</snippetsTree>
